Trial intelligence / Profile preview

Phase 3 study of BMS-986165 vs placebo and apremilast in moderate-to-severe plaque psoriasis

2018-001925-24Phase 3Unknown

Sponsor
Bristol Myers Squibb
Start
Aug 2018
Modality
Small Molecules
Countries
1
01

Overview

A Phase 3 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Status: unknown.

02

Drugs

deucravacitinib
03

Conditions

plaque psoriasis

Beyond the preview

Go deeper on 2018-001925-24.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2018-001925-24.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call